\contentsline {chapter}{\numberline {1}Introduction}{1}{chapter.1}
\contentsline {section}{\numberline {1.1}Cancer Research in the Post-Genomic Era}{1}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Cancer as a Global Health Concern}{2}{subsection.1.1.1}
\contentsline {subsubsection}{\numberline {1.1.1.1}Genetics and Molecular Biology in Cancers}{3}{subsubsection.1.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}The Human Genome Revolution}{5}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}The First Human Genome Sequence}{5}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Impact of Genomics}{6}{subsubsection.1.1.2.2}
\contentsline {subsection}{\numberline {1.1.3}Technologies to Enable Genetics Research}{7}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}DNA Sequencing and Genotyping Technologies}{7}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Microarrays and Quantitative Technologies}{7}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Massively Parallel ``Next Generation'' Sequencing}{8}{subsubsection.1.1.3.3}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.1}Molecular Profiling with Genomics Technology}{10}{subsubsubsection.1.1.3.3.1}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.2}Established Sequencing Technologies}{10}{subsubsubsection.1.1.3.3.2}
\contentsline {subsubsubsection}{\numberline {1.1.3.3.3}Emerging Sequencing Technologies}{11}{subsubsubsection.1.1.3.3.3}
\contentsline {subsubsection}{\numberline {1.1.3.4}Bioinformatics as Interdisciplinary Genomic Analysis}{13}{subsubsection.1.1.3.4}
\contentsline {subsection}{\numberline {1.1.4}Follow-up Large-Scale Genomics Projects}{14}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Cancer Genomes}{15}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}The Cancer Genome Atlas Project}{16}{subsubsection.1.1.5.1}
\contentsline {subsubsection}{\numberline {1.1.5.2}The International Cancer Genome Consortium}{16}{subsubsection.1.1.5.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.1}Findings from Cancer Genomes}{17}{subsubsubsection.1.1.5.2.1}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.2}Genomic Comparisons Across Cancer Tissues}{18}{subsubsubsection.1.1.5.2.2}
\contentsline {subsubsubsection}{\numberline {1.1.5.2.3}Cancer Genomic Data Resouces}{19}{subsubsubsection.1.1.5.2.3}
\contentsline {subsection}{\numberline {1.1.6}Genomic Cancer Medicine}{20}{subsection.1.1.6}
\contentsline {subsubsection}{\numberline {1.1.6.1}Cancer Genes and Driver Mutations}{20}{subsubsection.1.1.6.1}
\contentsline {subsubsection}{\numberline {1.1.6.2}Personalised or Precision Cancer Medicine}{21}{subsubsection.1.1.6.2}
\contentsline {subsubsubsection}{\numberline {1.1.6.2.1}Molecular Diagnostics and Pan-Cancer Medicine}{22}{subsubsubsection.1.1.6.2.1}
\contentsline {subsubsection}{\numberline {1.1.6.3}Targeted Therapeutics and Pharmacogenomics}{22}{subsubsection.1.1.6.3}
\contentsline {subsubsubsection}{\numberline {1.1.6.3.1}Targeting Oncogenic Driver Mutations}{23}{subsubsubsection.1.1.6.3.1}
\contentsline {subsubsection}{\numberline {1.1.6.4}Systems and Network Biology}{23}{subsubsection.1.1.6.4}
\contentsline {subsubsubsection}{\numberline {1.1.6.4.1} Network Medicine, and Polypharmacology}{26}{subsubsubsection.1.1.6.4.1}
\contentsline {section}{\numberline {1.2}A Synthetic Lethal Approach to Cancer Medicine}{27}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Synthetic Lethal Genetic Interactions}{27}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Synthetic Lethal Concepts in Genetics}{28}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Studies of Synthetic Lethality}{29}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Synthetic Lethal Pathways and Networks}{29}{subsubsection.1.2.3.1}
\contentsline {subsubsubsection}{\numberline {1.2.3.1.1}Evolution of Synthetic Lethality}{30}{subsubsubsection.1.2.3.1.1}
\contentsline {subsection}{\numberline {1.2.4}Synthetic Lethal Concepts in Cancer}{31}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}Clinical Impact of Synthetic Lethality in Cancer}{32}{subsection.1.2.5}
\contentsline {subsection}{\numberline {1.2.6}High{}-throughput Screening for Synthetic Lethality}{34}{subsection.1.2.6}
\contentsline {subsubsection}{\numberline {1.2.6.1}Synthetic Lethal Screens}{36}{subsubsection.1.2.6.1}
\contentsline {subsection}{\numberline {1.2.7}Computational Prediction of Synthetic Lethality}{39}{subsection.1.2.7}
\contentsline {subsubsection}{\numberline {1.2.7.1}Bioinformatics Approaches to Genetic Interactions}{39}{subsubsection.1.2.7.1}
\contentsline {subsubsection}{\numberline {1.2.7.2}Comparative Genomics}{40}{subsubsection.1.2.7.2}
\contentsline {subsubsection}{\numberline {1.2.7.3}Analysis and Modelling of Protein Data}{43}{subsubsection.1.2.7.3}
\contentsline {subsubsection}{\numberline {1.2.7.4}Differential Gene Expression}{45}{subsubsection.1.2.7.4}
\contentsline {subsubsection}{\numberline {1.2.7.5}Data Mining and Machine Learning}{46}{subsubsection.1.2.7.5}
\contentsline {subsubsection}{\numberline {1.2.7.6}Bimodality}{48}{subsubsection.1.2.7.6}
\contentsline {subsubsection}{\numberline {1.2.7.7}Rationale for Further Development}{49}{subsubsection.1.2.7.7}
\contentsline {section}{\numberline {1.3}E-cadherin as a Synthetic Lethal Target}{50}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}The \textit {CDH1} gene and it's Biological Functions}{50}{subsection.1.3.1}
\contentsline {subsubsection}{\numberline {1.3.1.1}Cytoskeleton}{50}{subsubsection.1.3.1.1}
\contentsline {subsubsection}{\numberline {1.3.1.2}Extracellular and Tumour Micro-Environment}{51}{subsubsection.1.3.1.2}
\contentsline {subsubsection}{\numberline {1.3.1.3}Cell-Cell Adhesion and Signalling}{51}{subsubsection.1.3.1.3}
\contentsline {subsection}{\numberline {1.3.2}\textit {CDH1} as a Tumour (and Invasion) Suppressor}{51}{subsection.1.3.2}
\contentsline {subsubsection}{\numberline {1.3.2.1}Breast Cancers and Invasion}{51}{subsubsection.1.3.2.1}
\contentsline {subsection}{\numberline {1.3.3}Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{52}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Somatic Mutations}{53}{subsection.1.3.4}
\contentsline {subsubsection}{\numberline {1.3.4.1}Mutation Rate}{53}{subsubsection.1.3.4.1}
\contentsline {subsubsection}{\numberline {1.3.4.2}Co-occuring Mutations}{54}{subsubsection.1.3.4.2}
\contentsline {subsection}{\numberline {1.3.5}Models of \textit {CDH1} loss in cell lines}{55}{subsection.1.3.5}
\contentsline {section}{\numberline {1.4}Summary and Research Direction of Thesis}{55}{section.1.4}
\contentsline {chapter}{\numberline {2}Methods and Resources}{60}{chapter.2}
\contentsline {section}{\numberline {2.1}Bioinformatics Resources for Genomics Research}{60}{section.2.1}
\contentsline {subsection}{\numberline {2.1.1}Public Data and Software Packages}{60}{subsection.2.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.1}Cancer Genome Atlas Data}{61}{subsubsection.2.1.1.1}
\contentsline {subsubsection}{\numberline {2.1.1.2}Reactome and Annotation Data}{62}{subsubsection.2.1.1.2}
\contentsline {section}{\numberline {2.2}Data Handling}{62}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Normalisation}{62}{subsection.2.2.1}
\contentsline {subsection}{\numberline {2.2.2}Sample Triage}{64}{subsection.2.2.2}
\contentsline {subsection}{\numberline {2.2.3}Metagenes and the Singular Value Decomposition}{64}{subsection.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.3.1}Candidate Triage and Integration with Screen Data}{65}{subsubsection.2.2.3.1}
\contentsline {section}{\numberline {2.3}Techniques}{66}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Statistical Procedures and Tests}{66}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Gene Set Over-representation Analysis}{67}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}Clustering}{67}{subsection.2.3.3}
\contentsline {subsection}{\numberline {2.3.4}Heatmap}{67}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}Modeling and Simulations}{68}{subsection.2.3.5}
\contentsline {subsubsection}{\numberline {2.3.5.1}Receiver Operating Characteristic (Performance)}{69}{subsubsection.2.3.5.1}
\contentsline {subsection}{\numberline {2.3.6}Resampling Analysis}{69}{subsection.2.3.6}
\contentsline {section}{\numberline {2.4}Pathway Structure Methods}{70}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Network and Graph Analysis}{70}{subsection.2.4.1}
\contentsline {subsection}{\numberline {2.4.2}Sourcing Graph Structure Data}{71}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Constructing Pathway Subgraphs}{71}{subsection.2.4.3}
\contentsline {subsection}{\numberline {2.4.4}Network Analysis Metrics}{71}{subsection.2.4.4}
\contentsline {section}{\numberline {2.5}Implementation}{73}{section.2.5}
\contentsline {subsection}{\numberline {2.5.1}Computational Resources and Linux Utilities}{73}{subsection.2.5.1}
\contentsline {subsection}{\numberline {2.5.2}R Language and Packages}{74}{subsection.2.5.2}
\contentsline {subsection}{\numberline {2.5.3}High Performance and Parallel Computing}{77}{subsection.2.5.3}
\contentsline {chapter}{\numberline {3}Methods Developed During Thesis}{79}{chapter.3}
\contentsline {section}{\numberline {3.1}A Synthetic Lethal Detection Methodology}{79}{section.3.1}
\contentsline {section}{\numberline {3.2}Synthetic Lethal Simulation and Modelling}{81}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}A Model of Synthetic Lethality in Expression Data}{82}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Simulation Procedure}{86}{subsection.3.2.2}
\contentsline {section}{\numberline {3.3}Detecting Simulated Synthetic Lethal Partners}{89}{section.3.3}
\contentsline {subsection}{\numberline {3.3.1}Binomial Simulation of Synthetic lethality}{89}{subsection.3.3.1}
\contentsline {subsection}{\numberline {3.3.2}Multivariate Normal Simulation of Synthetic lethality}{91}{subsection.3.3.2}
\contentsline {subsubsection}{\numberline {3.3.2.1}Multivariate Normal Simulation with Correlated Genes}{94}{subsubsection.3.3.2.1}
\contentsline {subsubsection}{\numberline {3.3.2.2}Specificity with Query-Correlated Pathways}{101}{subsubsection.3.3.2.2}
\contentsline {subsubsubsection}{\numberline {3.3.2.2.1}Importance of Directional Testing}{101}{subsubsubsection.3.3.2.2.1}
\contentsline {section}{\numberline {3.4}Graph Structure Methods}{103}{section.3.4}
\contentsline {subsection}{\numberline {3.4.1}Upstream and Downstream Gene Detection}{103}{subsection.3.4.1}
\contentsline {subsubsection}{\numberline {3.4.1.1}Permutation Analysis for Statistical Significance}{104}{subsubsection.3.4.1.1}
\contentsline {subsubsection}{\numberline {3.4.1.2}Ranking Based on Biological Context}{105}{subsubsection.3.4.1.2}
\contentsline {subsection}{\numberline {3.4.2}Simulating Gene Expression from Graph Structures}{106}{subsection.3.4.2}
\contentsline {section}{\numberline {3.5}Customised Functions and Packages Developed}{110}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Synthetic Lethal Interaction Prediction Tool}{110}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Data Visualisation}{111}{subsection.3.5.2}
\contentsline {subsection}{\numberline {3.5.3}Extensions to the iGraph Package}{113}{subsection.3.5.3}
\contentsline {subsubsection}{\numberline {3.5.3.1}Sampling Simulated Data from Graph Structures}{113}{subsubsection.3.5.3.1}
\contentsline {subsubsection}{\numberline {3.5.3.2}Plotting Directed Graph Structures}{113}{subsubsection.3.5.3.2}
\contentsline {subsubsection}{\numberline {3.5.3.3}Computing Information Centrality}{114}{subsubsection.3.5.3.3}
\contentsline {subsubsection}{\numberline {3.5.3.4}Testing Pathway Structure with Permutation Testing}{114}{subsubsection.3.5.3.4}
\contentsline {subsubsection}{\numberline {3.5.3.5}Metapackage to Install iGraph Functions}{115}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{116}{chapter.4}
\contentsline {section}{\numberline {4.1}Synthetic lethal genes in breast cancer}{117}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic lethal pathways in breast cancer}{119}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression profiles of synthetic lethal partners}{119}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup pathway analysis}{120}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparison of synthetic lethal gene candidates}{122}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Comparison with differential expression}{122}{subsection.4.2.1}
\contentsline {subsection}{\numberline {4.2.2}Comparison with primary siRNA screen candidates}{122}{subsection.4.2.2}
\contentsline {subsubsection}{\numberline {4.2.2.1}Comparison with correlation}{125}{subsubsection.4.2.2.1}
\contentsline {subsubsection}{\numberline {4.2.2.2}Comparison with viability}{127}{subsubsection.4.2.2.2}
\contentsline {subsubsection}{\numberline {4.2.2.3}Comparison of screen at pathway level}{128}{subsubsection.4.2.2.3}
\contentsline {subsubsubsection}{\numberline {4.2.2.3.1}Resampling of genes for pathway enrichment}{128}{subsubsubsection.4.2.2.3.1}
\contentsline {subsection}{\numberline {4.2.3}Comparison with secondary screen siRNA screen candidates}{132}{subsection.4.2.3}
\contentsline {subsubsection}{\numberline {4.2.3.1}Comparison of candidate SL Pathways}{132}{subsubsection.4.2.3.1}
\contentsline {section}{\numberline {4.3}Mutation, Copy Number, and Methylation}{132}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Synthetic lethality by DNA copy number}{134}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Synthetic lethality by somatic mutation}{134}{subsection.4.3.2}
\contentsline {subsubsection}{\numberline {4.3.2.1}Mutation analysis}{134}{subsubsection.4.3.2.1}
\contentsline {subsection}{\numberline {4.3.3}ANOVA of Expression Predictors}{134}{subsection.4.3.3}
\contentsline {section}{\numberline {4.4}Global Synthetic Lethality}{135}{section.4.4}
\contentsline {subsection}{\numberline {4.4.1}Hub Genes}{135}{subsection.4.4.1}
\contentsline {section}{\numberline {4.5}Metagene Analysis}{135}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Pathway expression}{135}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Somatic mutation}{135}{subsection.4.5.2}
\contentsline {subsection}{\numberline {4.5.3}Synthetic lethal metagenes}{135}{subsection.4.5.3}
\contentsline {section}{\numberline {4.6}Replication in stomach cancer}{135}{section.4.6}
\contentsline {section}{\numberline {4.7}Replication in cell line encyclopaedia}{136}{section.4.7}
\contentsline {section}{\numberline {4.8}Summary}{137}{section.4.8}
\contentsline {paragraph}{Aims}{147}{section*.89}
\contentsline {paragraph}{Summary}{148}{section*.90}
\contentsline {chapter}{\numberline {5}Synthetic Lethal Pathway Structure}{152}{chapter.5}
\contentsline {paragraph}{Aims}{152}{section*.91}
\contentsline {paragraph}{Summary}{152}{section*.92}
\contentsline {section}{\numberline {5.1}Reactome Network structure and Information Centrality as a measure of gene essentiality}{152}{section.5.1}
\contentsline {section}{\numberline {5.2}Synthetic lethal genes in synthetic lethal pathways}{153}{section.5.2}
\contentsline {section}{\numberline {5.3}Centrality and connectivity of synthetic lethal genes}{153}{section.5.3}
\contentsline {section}{\numberline {5.4}Upstream or downstream synthetic lethal candidates}{153}{section.5.4}
\contentsline {section}{\numberline {5.5}Hierachical approach}{153}{section.5.5}
\contentsline {section}{\numberline {5.6}Discussion}{153}{section.5.6}
\contentsline {section}{\numberline {5.7}Conclusion}{153}{section.5.7}
\contentsline {chapter}{\numberline {6}Simulation and Modeling of Synthetic Lethal Pathways}{154}{chapter.6}
\contentsline {paragraph}{Aims}{154}{section*.93}
\contentsline {paragraph}{Summary}{154}{section*.94}
\contentsline {section}{\numberline {6.1}Simulations and Modelling Synthetic Lethality in Expression Data}{156}{section.6.1}
\contentsline {section}{\numberline {6.2}Simulations over simple graph structures}{157}{section.6.2}
\contentsline {subsection}{\numberline {6.2.1}Performance}{157}{subsection.6.2.1}
\contentsline {subsection}{\numberline {6.2.2}Synthetic lethality across graph stuctures}{157}{subsection.6.2.2}
\contentsline {subsection}{\numberline {6.2.3}Performance with inhibition links}{157}{subsection.6.2.3}
\contentsline {subsection}{\numberline {6.2.4}Performance with 20,000 genes}{157}{subsection.6.2.4}
\contentsline {section}{\numberline {6.3}Simulations over pathway-based graphs}{157}{section.6.3}
\contentsline {section}{\numberline {6.4}Comparing methods}{157}{section.6.4}
\contentsline {subsection}{\numberline {6.4.1}SLIPT and Chi-Squared}{157}{subsection.6.4.1}
\contentsline {subsubsection}{\numberline {6.4.1.1}Correlated query genes}{157}{subsubsection.6.4.1.1}
\contentsline {subsection}{\numberline {6.4.2}Correlation}{157}{subsection.6.4.2}
\contentsline {subsection}{\numberline {6.4.3}Bimodality with BiSEp}{157}{subsection.6.4.3}
\contentsline {chapter}{\numberline {7}Discussion}{158}{chapter.7}
\contentsline {paragraph}{Aims}{158}{section*.95}
\contentsline {paragraph}{Summary}{158}{section*.96}
\contentsline {section}{\numberline {7.1}Significance}{160}{section.7.1}
\contentsline {section}{\numberline {7.2}Future Directions}{161}{section.7.2}
\contentsline {section}{\numberline {7.3}Conclusion}{162}{section.7.3}
\contentsline {chapter}{\numberline {8}Conclusion}{163}{chapter.8}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }References}{164}{subsubsection.3.5.3.5}
\contentsline {chapter}{\numberline {A}Sample Quality}{190}{appendix.A}
\contentsline {section}{\numberline {A.1}Sample Correlation}{190}{section.A.1}
\contentsline {section}{\numberline {A.2}Replicate Samples in TCGA Breast}{192}{section.A.2}
\contentsline {chapter}{\numberline {B}Software Used for Thesis}{196}{appendix.B}
\contentsline {chapter}{\numberline {C}Secondary Screen Data}{205}{appendix.C}
\contentsline {chapter}{\numberline {D}Mutation Analysis in Breast Cancer}{207}{appendix.D}
\contentsline {section}{\numberline {D.1}Synthetic Lethal Genes and Pathways}{207}{section.D.1}
\contentsline {section}{\numberline {D.2}Synthetic Lethal Expression Profiles}{208}{section.D.2}
\contentsline {section}{\numberline {D.3}Comparison to Primary Screen}{211}{section.D.3}
\contentsline {subsection}{\numberline {D.3.1}Resampling Analysis}{213}{subsection.D.3.1}
\contentsline {section}{\numberline {D.4}Compare SLIPT genes}{215}{section.D.4}
\contentsline {section}{\numberline {D.5}Metagene Analysis}{217}{section.D.5}
\contentsline {section}{\numberline {D.6}Mutation Variation}{218}{section.D.6}
\contentsline {subsection}{\numberline {D.6.1}Mutation Frequency}{218}{subsection.D.6.1}
\contentsline {subsection}{\numberline {D.6.2}PI3K Mutation Expression}{219}{subsection.D.6.2}
\contentsline {chapter}{\numberline {E}Metagene Expression Profiles}{224}{appendix.E}
\contentsline {chapter}{\numberline {F}Expression Analysis in Stomach Cancer}{231}{appendix.F}
\contentsline {chapter}{\numberline {G}Mutation Analysis in Stomach Cancer}{232}{appendix.G}
